Windward Bio Group AG(WWB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.42 | Insider Own | - | Shs Outstand | 15.4M | Perf Week | -14.79% |
| Market Cap | 1.33B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | - |
| Enterprise Value | 1.14B | PEG | - | EPS next Q | - | Inst Own | 8.95% | Short Float | - | Perf Quarter | - |
| Income | -0.07B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | 0.00B | P/B | 1.41 | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | 32.34% |
| Book/sh | 17.21 | P/C | 7.13 | EPS past 3/5Y | - | ROE | - | 52W High | -28.54% ($33.99) | Perf Year | - |
| Cash/sh | 3.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.65% | 52W Low | 32.34% ($18.35) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 31.74% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 8.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.57 | EPS Q/Q | -31% | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.57 | Sales Q/Q | - | SMA20 | -6.14% ($25.87) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -6.14% ($25.87) | Rel Volume | 0.32 | Prev Close | $24.01 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -6.14% ($25.87) | Avg Volume(3M) | 0.49M | Price | $24.28 |
| IPO | 2026/11/13 | Option/Short | No/Yes | Trades | 1628 | Volume | 158,632 | Change | 1.15% |
🫁 A Switzerland-based clinical-stage biotechnology company. It develops long-acting antibody drugs designed to significantly extend dosing intervals, targeting respiratory inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A single antibody that blocks inflammatory signaling molecules is in Phase 2 clinical trials, and a bispecific antibody that blocks two inflammatory pathways simultaneously is in early-stage clinical trials. There are currently no approved products or revenue.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded less than usual. That is 32% of its average volume.
WWB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.9%.
Tap to view numbers
It ranks #128 of 598 in the industry
Based on market cap of $1B.
FAQ
WWB belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of WWB is approximately $1.3B, ranking 2,290 within its sector.
WWB has recorded a 52-week high of $33.99 and a low of $18.35.